Background {#Sec1}
==========

Pulmonary edema is classified into cardiogenic and non-cardiogenic types. Cardiogenic pulmonary edema is caused by hydrostatic factors (e.g., volume overload and/or pulmonary hypertension caused by inadequate cardiac function), whereas non-cardiogenic pulmonary edema is caused by vascular permeability, which is also known as permeability pulmonary edema \[[@CR1]\]. Both forms of pulmonary edema are associated with increased extravascular lung water. Extravascular lung water (EVLW) can be measured by the transpulmonary thermodilution technique and is strongly correlated with actual lung weight at autopsy and at donor surgery, which reflects pulmonary edema in humans \[[@CR2]--[@CR4]\].

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is one of the most common types of permeability pulmonary edema. Among patients with ALI/ARDS, an increase in EVLW is associated with increased risk of mortality \[[@CR5]\]. In most types of cardiogenic pulmonary edema, increases in EVLW are caused by volume overload by fluid infusion in the presence of inadequate cardiac function. By comparison, the risk factors for permeability pulmonary edema in ALI/ARDS, for which appropriate interventions are expected in critical care, are still unknown. In terms of the pathophysiology of ALI/ARDS, the most important treatment target is to inhibit the increase in pulmonary permeability; currently, however, there are no effective agents and/or ventilator strategies for use in clinical settings. Our preliminary study showed that hemodynamic and osmolarity parameters were risk factors for hydrostatic and permeability pulmonary edema \[[@CR6]\]. This is important because hemodynamic and osmolarity factors could be controlled by the physician. In this context, the aim of this study was to identify hemodynamic and/or osmolarity risk factors for an increase of extravascular lung water index (EVLWI) that could be controlled in clinical settings as possible treatment targets for ALI/ARDS.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

Between March 2009 and August 2011, we conducted a multicenter observational study to assess the clinical diagnosis of cardiogenic and non-cardiogenic pulmonary edema, which were assessed using the transpulmonary thermodilution technique \[[@CR7]\]. The protocol of this subgroup analysis was approved by the institutional review boards of all participating institutions, and written informed consent was provided by each patient's next of kin. The investigation was registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN-CTR ID: UMIN000003627).

Patients {#Sec4}
--------

The inclusion and exclusion criteria were the same as those in our previous study \[[@CR7]\]. Patients aged \>15 years old were eligible if they required mechanical ventilation, had a PaO~2~/FiO~2~ ratio of ≤300 mmHg, had bilateral infiltration on chest X-ray images, and were monitored by transpulmonary thermodilution. Exclusion criteria included the following: \>5 days since the onset of respiratory failure, chronic lung disease, history of a pulmonary operation, pulmonary embolism, severe peripheral artery disease, cardiac index (CI) of \<1.5 L/min · m^2^ with cardiogenic shock, lung contusion or burns, or the attending physician considered the patient as inappropriate for this study. Data from 207 patients with ALI/ARDS that was diagnosed by three or more experts in intensive care, respiratory, and cardiology, with appropriate clinical findings (e.g., medical history, physiological findings, radiological data, laboratory data, and echocardiography), were analyzed in this study.

Measurements {#Sec5}
------------

Transpulmonary thermodilution was performed using the PiCCO® monitor (Pulsion Medical Systems SE, Munich, Germany) in all institutions. A 4- or 5-Fr femoral arterial thermistor-tipped catheter (PC2014L16 or PV2015L20; Pulsion Medical Systems SE) was inserted into the patient and was connected to the PiCCO® plus or PiCCO® 2 monitor. The PiCCO® monitor uses the single-thermal indicator technique to calculate volumetric parameters. A bolus of 15 mL of cold saline is injected through a central venous catheter, and thermal variation is detected by the thermistor at the tip of the arterial catheter. Cardiac output is calculated using the Stewart-Hamilton method. The mean transit time and the exponential downslope time of the transpulmonary thermodilution curve are also calculated by this system. Each value provided by the PiCCO® monitor was calculated as the mean of three bolus injections of normal saline \[[@CR8]\]. Each value was indexed according to the patient's height and ideal body weight using the following formula: Body weight (kg) = 50 + 0.91 (Height (cm) -- 152.4) for males and body weight = 45.5 + 0.91 (Height (cm) -- 152.5) for females, as previously reported \[[@CR9]\].

The transpulmonary thermodilution technique calculates the CI, global end-diastolic volume index (GEDVI) (corresponding to global diastolic cardiac volume in relation to preload), and EVLWI (a quantitative assessment of pulmonary edema \[[@CR2]--[@CR4]\] calculated as Extravascular lung water/Ideal body weight). Analysis of the arterial pulse contour by the PiCCO® monitor also provides other parameters, including continuous cardiac output and the stroke volume variation (SVV), which is the percentage in respiratory-induced stroke volume variation in relation to preload.

We conducted multivariate linear regression analyses to identify which of the following hemodynamic and osmolarity parameters were associated with EVLWI: GEDVI, SVV, and central venous pressure (CVP) as preload parameters, systemic vascular resistance index (SVRI) as afterload parameter, CI as hemodynamic parameter, and albumin (ALB) and serum osmolarity (OSM) as serum osmolarity parameters. OSM was calculated using the formula: OSM = 2(Na + K) + BS/18 + BUN/2.8, where Na = sodium concentration (mmol/L), K = potassium concentration (mmol/L), BS = blood sugar concentration (mg/dL), and BUN = blood urea nitrogen concentration (mg/dL). These data were obtained on the day of enrollment (day 0) and on days 1 and 2 after enrollment. OSM was only determined on day 0.

Statistical analysis {#Sec6}
--------------------

Statistical analyses were performed using SPSS software version 16.0 (IBM, Armonk, NY, USA). Univariate analyses were performed using Student's *t* test. Multivariate regression analyses were performed with a stepwise procedure to identify the statistically significant factors associated with the dependent variable, EVLWI. The independent variables were age, sex ('male' was treated as a variable), GEDVI, SVV, CVP, SVRI, CI, ALB, and OSM. Correlation analysis was performed using Pearson's correlation test. The analyses were performed for each day of measurement. All statistical analyses were considered significant at *P* \< 0.05.

Results {#Sec7}
=======

The characteristics and parameters measured in the 207 patients are summarized in Table [1](#Tab1){ref-type="table"}. The mean age was 66.7 years old. There were 134 males and 73 females, and 61.8% had sepsis. The mean APACHE II score, SOFA score, PaO~2~/FiO~2~ ratio, and lung injury score \[[@CR10]\] were 23.4, 10.7, 150.5 mmHg, and 2.3, respectively. The 28-day mortality rate was 40.6%. The comparison between survivor and non-survivor, age, APACHE II score, SOFA score, CVP on day 1, SVV on day 2, and CVP on day 2 were significantly different.Table 1**Patient characteristics**VariableAll casesSurvivorNon-survivor***P*** value*n*20712384Age (years)66.7 ± 16.863.9 ± 17.670.7 ± 14.9*0.004*Male134 (64.7%)77 (62.6%)57 (67.9%)0.437Sepsis, yes128 (61.8%)70 (56.9%)58 (69.0%)0.078APACHE II score23.4 ± 8.121.9 ± 7.825.6 ± 8.1*0.001*SOFA score10.7 ± 3.610.0 ± 3.211.8 ± 3.7*\<0.001*PaO~2~/FiO~2~ ratio (mmHg)150.5 ± 70.9155.8 ± 70.2142.8 ± 71.60.195Lung injury score2.3 ± 0.62.3 ± 0.62.3 ± 0.60.70228-day mortality rate84 (40.6%)0 (0%)84 (100%)-Day 0 EVLWI (mL/kg)18.5 ± 6.818.5 ± 6.918.5 ± 6.70.981 GEDVI (mL/m^2^)816.8 ± 205.7823.0 ± 211.8807.5 ± 197.20.595 SVV (%)15.7 ± 6.915.4 ± 7.316.1 ± 6.40.472 CVP (mmHg)10.2 ± 5.39.8 ± 4.910.7 ± 5.80.221 CI (L/min · m^2^)3.5 ± 1.33.6 ± 1.23.3 ± 1.30.171 SVRI (dyn · s · cm^−5^ · m^2^)1,805 ± 8661,716 ± 7071,932 ± 1,0430.083 ALB (g/dL)2.6 ± 0.72.6 ± 0.72.6 ± 0.70.509 OSM (mOsm/L)304.7 ± 16.7303.5 ± 15.6306.4 ± 18.10.227 PEEP (cmH~2~O)8.7 ± 4.78.8 ± 4.78.5 ± 4.80.720Day 1 EVLWI (mL/kg)17.7 ± 7.417.3 ± 7.218.4 ± 7.80.280 GEDVI (mL/m^2^)821.4 ± 222.5828.8 ± 222.3810.1 ± 223.70.561 SVV (%)14.2 ± 7.614.0 ± 8.714.6 ± 5.70.581 CVP (mmHg)10.6 ± 4.89.9 ± 4.411.7 ± 5.2*0.007* CI (L/min · m^2^)3.5 ± 1.23.6 ± 1.13.3 ± 1.30.119 SVRI (dyn · s · cm^−5^ · m^2^)1,880 ± 8521,865 ± 8731,902 ± 8240.767 ALB (g/dL)2.5 ± 0.62.5 ± 0.62.4 ± 0.60.304 PEEP (cmH~2~O)8.9 ± 5.29.0 ± 5.18.9 ± 5.50.934Day 2 EVLWI (mL/kg)16.4 ± 7.415.7 ± 6.417.7 ± 8.80.077 GEDVI (mL/m^2^)858.3 ± 238.2844.7 ± 237.2880.2 ± 239.70.315 SVV (%)12.4 ± 5.910.9 ± 5.514.7 ± 5.8*\<0.001* CVP (mmHg)10.4 ± 5.09.6 ± 4.311.7 ± 5.7*0.004* CI (L/min · m^2^)3.7 ± 1.33.7 ± 1.33.7 ± 1.30.920 SVRI (dyn · s · cm^−5^ · m^2^)1,791 ± 7331,791 ± 7331,791 ± 7330.977 ALB (g/dL)2.5 ± 0.62.5 ± 0.62.5 ± 0.60.880 PEEP (cmH~2~O)8.5 ± 5.08.5 ± 4.98.5 ± 5.30.947Values are means ± standard deviation or *n* (%). *P* value: survivor vs. non-survivor. The italicized values are statistically significant. *APACHE* acute physiology and chronic health evaluation, *SOFA* sequential organ failure assessment, *EVLWI* extravascular lung water index, *GEDVI* global end-diastolic volume index, *SVV* stroke volume variation, *CVP* central venous pressure, *CI* cardiac index, *SVRI* systemic vascular resistance index, *ALB* serum albumin, *OSM* calculated serum osmotic pressure (OSM = 2(Na + K) + BS / 18 + BUN / 2.8, where Na = sodium concentration (mmol/L), K = potassium concentration (mmol/L), BS = blood sugar concentration (mg/dL), and BUN = blood urea nitrogen concentration (mg/dL)), *PEEP* positive end-expiratory pressure.

Table [2](#Tab2){ref-type="table"} shows the results of the multivariate regression analysis performed using the stepwise procedure. GEDVI and CI were significantly associated with EVLWI on day 0 (*P* = 0.002 and *P* = 0.023, respectively). GEDVI and sex were significantly associated with EVLWI on day 1 (*P* \< 0.001 and *P* = 0.015, respectively). Sex, GEDVI, and SVRI were significantly associated with EVLWI on day 2 (*P* = 0.002, *P* = 0.003, and *P* = 0.049, respectively).Table 2**Results of multivariate regression analysis with EVLWI as the dependent variable**Variable***P*** valueRegression coefficient (95% confidence interval)Standard regression coefficientDay 0 GEDVI0.0020.009 (0.004, 0.015)0.272 CI0.023−1.045 (−1.941, −0.148)−0.195  *R* ^2^ = 0.0760.003Day 1 GEDVI\<0.0010.011 (0.006, 0.017)0.330 Sex (male)0.015−3.045 (−5.500, −0.590)−0.188  *R* ^2^ = 0.135\<0.001Day 2 Sex (male)0.002−4.161 (−6.764, −1.557)−0.256 GEDVI0.0030.008 (0.003, 0.014)0.251 SVRI0.0490.002 (0.000, 0.003)0.158 Age0.0510.074 (0.000, 0.148)0.162  *R* ^2^ = 0.181\<0.001Regression analyses were performed using the stepwise procedure. *EVLWI* extravascular lung water index, *GEDVI* global end-diastolic volume index, *CI* cardiac index, *SVRI* systemic vascular resistance index.

Figure [1](#Fig1){ref-type="fig"} shows the results of Pearson's correlation test between GEDVI and EVLWI. Pearson's correlation coefficients in day 0, 1, and 2 were 0.283, 0.343, and 0.264, respectively (*P* \< 0.001 in each day).Figure 1**Correlation between extravascular lung water index (EVLWI) and global end-diastolic volume index (GEDVI) in each day.** Pearson's correlation coefficients in days 0, 1, and 2 were 0.283, 0.343, and 0.264, respectively (*P* \< 0.001 in each day).

Discussion {#Sec8}
==========

The results of multivariate regression analysis suggested that in patients with ALI/ARDS, EVLWI was strongly associated with GEDVI measured for 3 days after enrollment in this study. The management of hemodynamic status by diuresis and limited fluid infusion in patients with cardiogenic pulmonary edema is already well established \[[@CR11]\]. By contrast, the management of permeability pulmonary edema in ALI/ARDS is still not well defined. Because the severity of cardiogenic pulmonary edema is related to the patient's hemodynamic status, then logically, the hemodynamic monitoring technique should follow this pathophysiology. However, in patients with ALI/ARDS, permeability pulmonary edema is not directly proportional to hemodynamic parameters \[[@CR7]\]. In the present study, EVLWI was used to quantify pulmonary edema and was strongly associated with GEDVI measured on all 3 days, suggesting that appropriate control of the circulating blood volume is an important factor in the management of not only cardiogenic edema but also permeability pulmonary edema. Consequently, GEDVI could also be a target for the management of ALI/ARDS.

Options for fluid management in patients with ALI/ARDS have already been assessed in a randomized controlled trial, where a conservative fluid strategy to control blood volume, by avoiding excessive water balance, improved the oxygenation index, lung injury score, and ventilator-free days but did not affect mortality \[[@CR12]\]. Another study showed that mortality was increased in patients who did not receive adequate fluid management (an initial fluid bolus and avoidance of a positive water balance for 1 week) \[[@CR13]\]. Although EVLWI and GEDVI were not evaluated in those studies, adequate blood volume management may improve lung function. GEDVI is an index of preload regulation. Although the management of blood volume improves lung function \[[@CR12], [@CR13]\], target GEDVI levels have not been defined. In fact, the target GEDVI should be conservative, with limited fluid infusion, to avoid worsening of EVLWI. However, if fluid management is too conservative, it may result in inadequate blood volume that can cause organ ischemia. Therefore, an appropriate target of GEDVI should be established \[[@CR14]\]. Moreover, recent studies have shown that pulmonary permeability can be monitored and quantified using the transpulmonary thermodilution technique \[[@CR7], [@CR15]--[@CR17]\]. The target GEDVI level may need to be adjusted according to the severity of pulmonary permeability by evaluating the cutoff value for increases in EVLWI, although this needs to be investigated in future studies. However, in tradition, other preload parameters (CVP, SVV, etc.) did not show the target value; therefore, it is unclear whether the target GEDVI could be shown or not.

In a preliminary study, serum osmolarity factors, such as decreased ALB and increased OSM, were positively associated with EVLWI \[[@CR6]\], which was not confirmed in this study. In patients with ALI/ARDS, it was reported that albumin infusion and diuresis did not improve mortality, but did improve oxygenation \[[@CR18], [@CR19]\]. These preliminary results suggest that serum osmolarity factors may decrease EVLWI, although this was not statistically significant in our study. The type of fluid being used to control blood volume may be an important factor in patients with severely increased pulmonary permeability. Current data suggest that fluid resuscitation of albumin for severe sepsis and septic shock is recommended over hydroxyethyl starch \[[@CR20]\], which can be used in the early phase of ALI/ARDS resuscitation without worsening EVLWI \[[@CR21]\]. Although ALB and OSM were not significantly associated with EVLWI in the present study, the type of fluid used for resuscitation should be assessed in future studies.

In the present study, most of the significant parameters were from hemodynamics (GEDVI, CI, and SVRI). However, sex was other significant parameter on days 2 and 3. These results showed that females had advantage for EVLWI increase. Previous study showed that gender affected the normal range of GEDVI \[[@CR22]\]; therefore, there is a possibility that gender could affect EVLWI, because of strong relationship between EVLWI and GEDVI in our data.

Our data showed a 40.6% 28-day mortality rate, and the average APACHE II score was 23.4. The average age of the non-survivor cases was significantly older (survivor vs. non-survivor 63.9 vs. 70.7, *P* = 0.004), and the non-survivor cases had tendency of high GEDVI and EVLWI on later days. It might be a result of fluid management protocol, which was not defined in this study. These results also indicated that there might be better fluid management.

Our study has several limitations. First, it was conducted as a secondary subgroup study, which means that the results should be confirmed in a prospective study. Second, the severity of pulmonary permeability was not considered, and the classification of pulmonary permeability may alter the results.

Multivariate analysis showed that GEDVI was the most predictor for an increase in EVLWI. These results are consistent with those of earlier fluid management studies in patients with ALI/ARDS \[[@CR12], [@CR13]\]. To aid the clinical management of patients with ALI/ARDS, we suggest that EVLWI and GEDVI should be measured to examine their clinical relevance as potential therapeutic targets. This possibility should be confirmed in a future study.

Conclusions {#Sec9}
===========

EVLWI as a quantitative marker of pulmonary edema is strongly associated with GEDVI in patients with ALI/ARDS. Therefore, GEDVI may be a therapeutic target to help control extravascular lung water. Prospective studies are needed to examine the effects of targeting GEDVI for improving EVLWI and clinical outcomes in patients with ALI/ARDS.
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